Syn­dax is hit with a set­back dur­ing the AS­CO pre­view round as lead drug flops in mid-stage study

Let’s add one more big los­er to the lengthy ros­ter of wins and de­feats dur­ing the AS­CO pre­view round.

Syn­dax Phar­ma­ceu­ti­cals shares $SNDX were hit hard af­ter it re­leased ab­stracts fol­lowed by a press re­lease demon­strat­ing that a com­bi­na­tion of their HDAC enti­no­s­tat plus Keytru­da pro­duced an ob­jec­tive re­sponse rate of on­ly 11% in pre-treat­ed can­cer pa­tients — with a pro­gres­sion-free sur­vival rate of on­ly 2.5 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER